Express News | Bristol-Myers Squibb- Patients Experienced Consistent & Sustained Improvement in Echocardiographic Measures & Biomarkers After Upto 3.5 Years of Treatment
Express News | Bristol-Myers Squibb - Long-Term Follow-up Data From Phase 3 Study of Camzyos® (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm)
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Piper Ups Neurocrine to Overweight, Says '568 Still in the Game
Bristol-Myers Squibb (NYSE:BMY) Investors Are Sitting on a Loss of 17% If They Invested Three Years Ago
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Market Whales and Their Recent Bets on BMY Options
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Merck, Bristol Myers Cancer Drugs Included in September FDA Advisory Panel Meeting
Bristol-Myers Squibb Company's (NYSE:BMY) Latest 3.0% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Express News | Bristol-Myers Squibb Says FDA Schedules Oncologic Drugs Advisory Committee Meeting For September 26 To Discuss PD-L1 Expression Levels In Gastric And Esophageal Cancers
Express News | Bristol-Myers Squibb Co - Meeting to Discuss Pd-L1 Expression Levels in Gastric and Esophageal Cancers